血管炎症生物标志物用于心血管风险预后评估:一项Meta分析
该Meta分析系统检索MEDLINE队列研究,评估血管炎症生物标志物在临床危险因素基础上对心血管事件的增量预后价值,共纳入39项独立研究(175778人)。血管炎症生物标志物仅对复合终点和主要不良心血管事件(MACE)提供增量预后价值(Δ[c-index]分别为2.9%和3.1%),其中冠状动脉CT血管成像相关标志物对MACE的增量价值最高。
要点
- 冠状动脉CT血管成像高危斑块特征对MACE的增量预后价值Δ[c-index]为5.8%(95%CI 0.6-11.0)。
- 冠状动脉周围脂肪组织成像在冠状动脉粥样硬化范围和 高危斑块基础上对MACE的增量预后价值Δ[c-index]为8.2%(95%CI 4.0-12.5)。
- 循环炎症生物标志物及动脉PET/CT对MACE的增量预后价值有限,汇总Δ[c-index]仅3.1%。
核心结论
- 使用血管炎症生物标志物可增强心血管事件的风险区分能力,其中冠状动脉CT血管成像相关标志物(高危斑块和冠状动脉周围脂肪组织成像)对MACE的增量预后价值最高。
研究设计与样本
- 系统检索MEDLINE发表的队列研究,纳入无已知冠心病稳定患者的常见血管炎症生物标志物预后研究,最终定量合成39项独立研究(175778人),主要终点为使用炎症生物标志物预测MACE和死亡率的c-index差值(Δ[c-index]),计算I²检验异质性,研究注册于PROSPERO(CRD42020181158)。
诊断标准与关键数值
- 血管炎症生物标志物对复合终点的汇总Δ[c-index]为2.9%(95%CI 1.7-4.1),对MACE的汇总Δ[c-index]为3.1%(95%CI 1.8-4.5);冠状动脉CT血管成像高危斑块对MACE的Δ[c-index]为5.8%(95%CI 0.6-11.0),冠状动脉周围脂肪组织在冠状动脉粥样硬化范围和 高危斑块基础上对MACE的Δ[c-index]为8.2%(95%CI 4.0-12.5)。
临床应用与阅片要点
- 在临床风险因素基础上,冠状动脉CT血管成像的高危斑块特征和冠状动脉周围脂肪组织成像可提供对MACE的增量风险区分信息,阅片时可关注这些影像标志物用于风险预后评估。
局限性
- 已发表文献缺乏对其他风险分层改善指标、净临床获益或此类生物标志物在临床实践中成本效益的报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The purpose of this study was to systematically explore the added value of biomarkers of vascular inflammation for cardiovascular prognostication on top of clinical risk factors.
BACKGROUND: Measurement of biomarkers of vascular inflammation is advocated for the risk stratification for coronary heart disease (CHD).
METHODS: We systematically explored published reports in MEDLINE for cohort studies on the prognostic value of common biomarkers of vascular inflammation in stable patients without known CHD. These included common circulating inflammatory biomarkers (ie, C-reactive protein, interleukin-6 and tumor necrosis factor-a, arterial positron emission tomography/computed tomography and coronary computed tomography angiography-derived biomarkers of vascular inflammation, including anatomical high-risk plaque features and perivascular fat imaging. The main endpoint was the difference in c-index (Δ[c-index]) with the use of inflammatory biomarkers for major adverse cardiovascular events (MACEs) and mortality. We calculated I2 to test heterogeneity. This study is registered with PROSPERO (CRD42020181158).
RESULTS: A total of 104,826 relevant studies were screened and a final of 39 independent studies (175,778 individuals) were included in the quantitative synthesis. Biomarkers of vascular inflammation provided added prognostic value for the composite endpoint and for MACEs only (pooled estimate for Δ[c-index]% 2.9, 95% CI: 1.7-4.1 and 3.1, 95% CI: 1.8-4.5, respectively). Coronary computed tomography angiography-related biomarkers were associated with the highest added prognostic value for MACEs: high-risk plaques 5.8%, 95% CI: 0.6 to 11.0, and perivascular adipose tissue (on top of coronary atherosclerosis extent and high-risk plaques): 8.2%, 95% CI: 4.0 to 12.5). In meta-regression analysis, the prognostic value of inflammatory biomarkers was independent of other confounders including study size, length of follow-up, population event incidence, the performance of the baseline model, and the level of statistical adjustment. Limitations in the published literature include the lack of reporting of other metrics of improvement of risk stratification, the net clinical benefit, or the cost-effectiveness of such biomarkers in clinical practice.
CONCLUSIONS: The use of biomarkers of vascular inflammation enhances risk discrimination for cardiovascular events.
引用
- Antonopoulos, Angelopoulos, Papanikolaou, et al. Biomarkers of Vascular Inflammation for Cardiovascular Risk Prognostication: A Meta-Analysis. JACC Cardiovasc Imaging. 2021. PMID: 34801448. doi:10.1016/j.jcmg.2021.09.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。